HALO Earnings
Latest Revenue481.0M
Latest Net Income229.9M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $1.96 | 481.0M | 229.9M | +47.7% | +44.1% |
| Q1 2026 | $1.27 | 376.7M | 150.0M | +42.2% | +32.3% |
| Q4 2025 | -$1.20 | 451.8M | -141591000 | +51.6% | -211.1% |
| Q3 2025 | $1.49 | 354.3M | 175.2M | +22.1% | +38.0% |
| Q2 2025 | $1.36 | 325.7M | 165.2M | +40.8% | +86.3% |
| Q1 2025 | $0.96 | 264.9M | 118.1M | +35.2% | +57.4% |
| Q4 2024 | $1.08 | 298.0M | 137.0M | +29.5% | +63.6% |
| Q3 2024 | $1.08 | 290.1M | 137.0M | +34.3% | +74.2% |
| Q2 2024 | $0.73 | 231.4M | 93.2M | — | — |
| Q1 2024 | $0.61 | 195.9M | 76.8M | — | — |
| Q4 2023 | $0.66 | 230.0M | 85.4M | — | — |
| Q3 2023 | $0.62 | 216.0M | 81.8M | — | — |
Halozyme Therapeutics (HALO) — Earnings